azd8329
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2009 (NCT00935662)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HSD11B1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4-(4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl)benzoic acid
- 4-(4-(2-adamantylcarbamoyl)-5-tert-butylpyrazol-1-yl)benzoic acid
- azd8329
- azd8329
- azd8329
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01225939 | Phase 1 | Nov 1, 2010 | AstraZeneca, IQVIA |
| NCT01207089 | Phase 1 | Sep 1, 2010 | AstraZeneca, IQVIA |
| NCT00935662 | Phase 1 | Jul 1, 2009 | AstraZeneca, IQVIA |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AstraZeneca | For profit | 3 | 3 | 1 | 2009 |
| IQVIA | For profit | 3 | 0 | 1 | 2009 |
2 organizations
Page 1 / 1